 The novel coronavirus, SARS-CoV-2, has caused a global pandemic. To date, there have been no approved serological tests available for diagnosis, which makes it difficult to trace the virus's origin and spread. In this study, researchers developed three serological assays for detecting antibodies against SARS-CoV-2. The results show that most people infected with the virus seroconvert within two weeks of symptom onset. Additionally, the researchers found that the commercial S1-IGG or IgA-elises had lower specificity than the IgA-elisa, while the latter was more sensitive. These validated assays will be useful for diagnostic, seroepidemiologic, and vaccine evaluation studies. This article was authored by Nisreen MA Aukba, Marcellae Muller, Wentauli, and others.